MET and cancer: The AR pathway negatively regulates the expression of MET and C-MYC; thus, when endocrine therapy reduces androgen levels and inhibits the AR pathway, the inhibitory effect on MET and C-MYC is lessened, leading to the upregulation of MET and C-MYC signaling pathways, which ultimately results in increased cancer cell growth, dissemination and resistance [[56], [57], [58]].